Clinical Trial

A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)

Investigator
Complete title:
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura
Trial phase:
Phase I/II
Study ID:
NCT03395210
Local study ID:
RG1005018
Summary:
This is an adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/µL on two counts no sooner than 7 days apart in the 15 days before treatment begins.
Trial keywords:
Immune System Diseases, Pathologic Processes, Hemorrhagic Disorders
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Trial exclusions
Other exclusion criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us
phone 1-800-606-7800
Toll-free